US$ 26.94
tirzepatide 2023 Lilly Shows Superiority in SURMOUNT-3 and 4 Tirzepatide (ZEPBOUND) Approved for Chronic
Description
Most GI symptoms resolved on their own with time
In clinical trials encompassing over 10,000 participants with exposure periods up to 72 weeks, cancer incidence rates were low and comparable between tirzepatide and comparator groups

Warning signs include severe persistent abdominal pain, inability to pass stool or gas, persistent vomiting, abdominal distension, and fever with abdominal symptoms

CheqUp members can contact the clinical support team if they notice unusual skin sensitivity, tingling or suspected dermatological reactions
